Tests a once-monthly pill to prevent HIV-1 in women
Tests MK-8527, a monthly pill, against daily PrEP to prevent HIV-1.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Bloemfontein, Cape Town, Chatsworth, Durban, East London, Edendale, Johannesburg, Johnnesburg, Khayelitsha, Ladysmith, Ndevana, Phoenix, Pietermaritzburg, Pretoria, Somkhele - Mtubatuba, and Verulam, South AfricaSee the 21 sitesAlso in 2 other countries, 9 sites
- Trial code
- Registry title
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 4,580 people, planned
- Started
- 10 Nov 2025
- Expected to end
- 18 Oct 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MK-8527
- Emtricitabine/tenofovir disoproxil (FTC/TDF)
- Placebo matched to MK-8527
- Placebo matched to FTC/TDF
- Record updated
- 20 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 16 to 30 who do not have HIV and have recently had vaginal sex with a cisgender man. It tests a once-monthly pill to prevent HIV-1.
- Age
- 16 to 30 years
- Sex
- Women only (assigned female at birth and cisgender)
- Disease stage
- No HIV infection: negative HIV-1/HIV-2 test results.
- Earlier treatment
- Must not have ever taken cabotegravir, lenacapavir or any other long-acting HIV prevention product. Must not have had an HIV vaccine at any time, or monoclonal antibodies to HIV within 12 months before Day 1.
- Biomarker or test result
- Negative HIV-1/HIV-2 test results. Body weight of 35 kg (77 lb) or more.
Main reasons for not taking part
- Allergy or other reason not to take any part of the study treatment
- Acute or chronic hepatitis B infection
- Cancer within 5 years of screening, except treated basal or squamous cell skin cancer or in situ cervical cancer
- Needs any prohibited therapies from 30 days before Day 1 through the study
- Past HIV vaccine or monoclonal antibodies to HIV within 12 months before Day 1
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- The main inclusion criteria include but are not limited to the following:
- Is confirmed Human Immunodeficiency Virus (HIV)-uninfected based on negative HIV-1/HIV-2 test results
- Has been sexually active (2 vaginal intercourse encounters with cisgender male individual(s) within the last 3 months)
- Was assigned female sex at birth and is cisgender
- Weighs ≥35 kg
Who cannot take part
- Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration
- Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1
- Has hypersensitivity or other contraindication to any component of the study interventions
- Has evidence of acute or chronic hepatitis B infection
- Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
- Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time
- The main exclusion criteria include but are not limited to the following:
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 16 and 30 years old?
This trial is currently available in South Africa.
Also in 2 other countries, 9 sites
- Josha Research (Site 0045)Bloemfontein, South AfricaContact: Toll Free NumberNo longer taking part
- Desmond Tutu Health Foundation. Philippi Village (Site 0024)Cape Town, South AfricaContact: Study CoordinatorTaking people
- DTHF Masiphumelele Clinical Research Site (Site 0023)Cape Town, South AfricaContact: Study CoordinatorTaking people
- SA Medical Research Council - Chatsworth Clinical Research Site (Site 0026)Chatsworth, South AfricaContact: Toll Free NumberNo longer taking part
- Umlazi Clinical Research Site (Site 0047)Durban, South AfricaContact: Study CoordinatorTaking people
- Wits Maternal Adolescent and Child Health Research Unit (WMRU) (Site 0027)Durban, South AfricaContact: Study CoordinatorTaking people
- CAPRISA eThekwini Clinical Research Site (Site 0030)Durban, South AfricaContact: Toll Free NumberNo longer taking part
- SA Medical Research Council - Botha's Hill Clinical Research Site (Site 0035)Durban, South AfricaContact: Toll Free NumberNo longer taking part
- Synergy Biomed Research Institute (Site 0040)East London, South AfricaContact: Study CoordinatorTaking people
- SYNAPSE Research Clinic (Site 0043)Edendale, South AfricaContact: Study CoordinatorTaking people
- Wits RHI Ward 21 Clinical Research site (Site 0022)Johannesburg, South AfricaContact: Study CoordinatorTaking people
- Helen Joseph Hospital-Clinical HIV Research Unit (Site 0048)Johannesburg, South AfricaContact: Toll Free NumberNo longer taking part
- Perinatal HIV Research Unit (PHRU) (Site 0033)Johnnesburg, South AfricaContact: Study CoordinatorTaking people
- Vuka Research Clinic (Site 0025)Khayelitsha, South AfricaContact: Toll Free NumberNo longer taking part
- Qhakaza Mbokodo Research Clinic (Site 0028)Ladysmith, South AfricaContact: Study CoordinatorTaking people
- Foundation For Professional Development (Site 0031)Ndevana, South AfricaContact: Toll Free NumberNo longer taking part
- SA Medical Research Council - Phoenix Clinical Research Site (Site 0037)Phoenix, South AfricaContact: Study CoordinatorTaking people
- CAPRISA Vulindlela Clinical Research Site (Site 0029)Pietermaritzburg, South AfricaContact: Study CoordinatorTaking people
- Setshaba Research Centre (Site 0032)Pretoria, South AfricaContact: Study CoordinatorTaking people
- Africa Health Research Institute (AHRI) - Mtubatuba (Site 0049)Somkhele - Mtubatuba, South AfricaContact: Toll Free NumberNo longer taking part
- SA Medical Research Council - Verulam Clinical Research Site (Site 0036)Verulam, South AfricaContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.
Read full original descriptionShow less
The goals of this study are to learn:
* If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
The 2 groups in the trial
- MK-8527 + Placebo to FTC/TDFTreatment being tested
Participants will receive 11 mg MK-8527 once monthly (QM) and placebo matched to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) once daily (QD) for up to approximately 2 years. Participants will then receive open-label 200 mg FTC/245 mg TDF QD for an additional 28 days.
Treatment: MK-8527 and Placebo matched to FTC/TDF
- FTC/TDF + Placebo to MK-8527Existing treatment, for comparison
Participants will receive 200 mg FTC/245 mg TDF QD and placebo matched to MK-8527 QM for up to approximately 2 years. Participants will then receive open-label 200 mg FTC/245 mg TDF QD for an additional 28 days.
Treatment: Emtricitabine/tenofovir disoproxil (FTC/TDF) and Placebo matched to MK-8527
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women
- Plain-language title
- Tests a once-monthly pill to prevent HIV-1 in womenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07071623, who can take part
- Record updated
- 20 October 2026